290832-35-8

Upstream product

• 290832-34-7 5-chloro-2-(4-chlorophenyl)-1H-indole-3-propanoic acid 
• 74-88-4 methyl iodide 
• 371969-22-1 methyl 5-chloro-2-(4-chlorophenyl)-1-methyl-1H-indole-3-propanoate 

Downstream Products

• 371969-40-3 5-chloro-2-(4-chlorophenyl)-1-methyl-1H-indole-3-propanenitrile 
• 290832-15-4 phenylmethyl 4-{3-[5-chloro-2-(4-chlorophenyl )-1-methyl-1H-indol-3-yl]-1-oxopropyl}-3-oxo-1-piperazinecarboxylate 
• 290832-20-1 (3S)-1-{3-[5-chloro-2-(4-chlorophenyl)-1-methyl-1H-indol-3-yl]-1-oxopropyl}-4-methyl-3-(phenylmethyl)piperazine 

Relevant academic research and scientific papers

2-aryl indole derivative as antagonists of tachykinins

The present invention relates to compounds of the formula (I): wherein R1a, R1b, R2, R3, R4, R5, X and n are defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis and postherpetic neuralgia.

Azaindole derivatives and their use as therapeutic agents

The present invention relates to compounds of the formula (I): wherein: Het represents a heterocyclic residue selected from: where the dotted line in (b) represents an optional double bond; A completes a fused pyridine ring; and B completes a fused benzene or pyridine ring. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migaine, emesis or postherpetic neuralgia.

2-Aryl indole NK1 antagonists: Optimisation of the amide substituent

The in vivo properties of a series of 2-arylindole NK1 antagonists have been improved, by modification of the amide substituent. The 1-(2-methoxyphenyl)piperazine amide was identified as a major area of metabolism in the lead compound 1. Replacement of this amine moiety by a 4-benzyl-4-hydroxypiperidine resulted in a compound 18 with reduced clearance and improved central duration of action.

2-aryl indole derivatives and their use as therapeutic agents

The present invention relates compounds of the formula (I): wherein R1a, R1b; and R2 represent a variety of substituents; R3 represents an optionally substituted phenyl, biphenyl or naphthyl or heteroaryl group; R4 represents hydrogen, C1-6alkyl, carbonyl (=O), (CH2)pphenyl or a C1-2alkylene bridge across the piperidine ring; R5 and R6 each independently represent a variety of substituents; or R5 and R6 together are linked so as to form an optionally substituted 5-or 6-membered ring; X represents an oxygen or a sulfur atom, two hydrogen atoms, ═NH or ═N(C1-6alkyl); Y is a straight or branched C1-4alkylene, C2-4alkenylene or C2-4alkynylene chain; the dotted line represents an optional double bond; m is zero or an integer from 1 to 4; n is an integer from 1 to 4; and p is an integer from 1 to 4; or a pharmaceutically acceptable salt thereof. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migaine, emesis or postherpetic neuralgia.